Cargando…

Advances in mRNA Vaccines for Infectious Diseases

During the last two decades, there has been broad interest in RNA-based technologies for the development of prophylactic and therapeutic vaccines. Preclinical and clinical trials have shown that mRNA vaccines provide a safe and long-lasting immune response in animal models and humans. In this review...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Cuiling, Maruggi, Giulietta, Shan, Hu, Li, Junwei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2019
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6446947/ https://www.ncbi.nlm.nih.gov/pubmed/30972078 http://dx.doi.org/10.3389/fimmu.2019.00594

Ejemplares similares

Recent Advances in the Molecular Design and Delivery Technology of mRNA for Vaccination Against Infectious Diseases
por: Yang, Lu, et al.
Publicado: (2022)

Oral mRNA Vaccines Against Infectious Diseases- A Bacterial Perspective [Invited]
por: Jawalagatti, Vijayakumar, et al.
Publicado: (2022)

Clinical Analysis and Applications of mRNA Vaccines in Infectious Diseases and Cancer Treatment
por: Ankrah, Paa Kwesi, et al.
Publicado: (2023)

Advancing mRNA technologies for therapies and vaccines: An African context
por: Kairuz, Dylan, et al.
Publicado: (2022)

mRNA vaccines for cancer immunotherapy
por: Vishweshwaraiah, Yashavantha L., et al.
Publicado: (2022)

Recent advances in mRNA cancer vaccines: meeting challenges and embracing opportunities
por: Wang, Bolin, et al.
Publicado: (2023)

Potentialities and Challenges of mRNA Vaccine in Cancer Immunotherapy
por: Duan, Li-Juan, et al.
Publicado: (2022)

Lipid nanoparticle-based mRNA vaccines in cancers: Current advances and future prospects
por: Huang, Tao, et al.
Publicado: (2022)

Construction and immunogenicity of an mRNA vaccine against chikungunya virus
por: Liu, Jingjing, et al.
Publicado: (2023)

Amplifying mRNA vaccines: potential versatile magicians for oncotherapy
por: Hu, Chaoying, et al.
Publicado: (2023)

Influenza Viruses: Innate Immunity and mRNA Vaccines
por: Lee, SangJoon, et al.
Publicado: (2021)

Advances in mRNA vaccines
por: Li, Mengyun, et al.
Publicado: (2022)

The Development of mRNA Vaccines for Infectious Diseases: Recent Updates
por: Nitika,, et al.
Publicado: (2021)

Exploitation of tumor antigens and construction of immune subtype classifier for mRNA vaccine development in bladder cancer
por: Zhang, Xin, et al.
Publicado: (2022)

Immunization with a novel mRNA vaccine, TGGT1_216200 mRNA-LNP, prolongs survival time in BALB/c mice against acute toxoplasmosis
por: Zhang, Yizhuo, et al.
Publicado: (2023)

Comparison of the mucosal and systemic antibody responses in Covid-19 recovered patients with one dose of mRNA vaccine and unexposed subjects with three doses of mRNA vaccines
por: Liu, Shaojun, et al.
Publicado: (2023)

Recognition of Tumor-Associated Antigens and Immune Subtypes in Glioma for mRNA Vaccine Development
por: Ma, Shuai, et al.
Publicado: (2021)

An mRNA vaccine against rabies provides strong and durable protection in mice
por: Li, Miao, et al.
Publicado: (2023)

mRNA Vaccines: The Dawn of a New Era of Cancer Immunotherapy
por: Deng, Zhuoya, et al.
Publicado: (2022)

Comprehensive Analyses of Immune Subtypes of Stomach Adenocarcinoma for mRNA Vaccination
por: You, Weiqiang, et al.
Publicado: (2022)

mRNA melanoma vaccine revolution spurred by the COVID-19 pandemic
por: Xu, Ziyang, et al.
Publicado: (2023)

mRNA vaccines: a new opportunity for malaria, tuberculosis and HIV
por: Matarazzo, Laura, et al.
Publicado: (2023)

Dissecting Tumor Antigens and Immune Subtypes of Glioma to Develop mRNA Vaccine
por: Zhong, Hua, et al.
Publicado: (2021)

mRNA Vaccine: How to Meet the Challenge of SARS-CoV-2
por: Jin, Yingqi, et al.
Publicado: (2022)

mRNA vaccines for infectious diseases: principles, delivery and clinical translation
por: Chaudhary, Namit, et al.
Publicado: (2021)

mRNA vaccines: A novel weapon to control infectious diseases
por: Tian, Yuying, et al.
Publicado: (2022)

Identification of tumor antigens and immune landscapes for bladder urothelial carcinoma mRNA vaccine
por: Sun, Zhuolun, et al.
Publicado: (2023)

How far are the new wave of mRNA drugs from us? mRNA product current perspective and future development
por: Duan, Qiongyu, et al.
Publicado: (2022)

Literature Mining and Mechanistic Graphical Modelling to Improve mRNA Vaccine Platforms
por: Leonardelli, Lorena, et al.
Publicado: (2021)

Identification of Tumor Antigens and Immune Subtypes of Glioblastoma for mRNA Vaccine Development
por: Lin, Han, et al.
Publicado: (2022)

Seroconversion to mRNA SARS-CoV-2 Vaccines in Hematologic Patients
por: Fattizzo, Bruno, et al.
Publicado: (2022)

Analyses of circRNA and mRNA Profiles in Vogt–Koyanagi–Harada Disease
por: Shu, Jia, et al.
Publicado: (2021)

Neutralizing Potency of Prototype and Omicron RBD mRNA Vaccines Against Omicron Variant
por: Zang, Jinkai, et al.
Publicado: (2022)

The advances of adjuvants in mRNA vaccines
por: Xie, Chunyuan, et al.
Publicado: (2023)

From COVID-19 to Cancer mRNA Vaccines: Moving From Bench to Clinic in the Vaccine Landscape
por: Chakraborty, Chiranjib, et al.
Publicado: (2021)

mRNA-based modalities for infectious disease management
por: Zhang, Mengjie, et al.
Publicado: (2022)

A single vaccination of nucleoside-modified Rabies mRNA vaccine induces prolonged highly protective immune responses in mice
por: Bai, Shimeng, et al.
Publicado: (2023)

SARS-CoV-2 bivalent mRNA vaccine with broad protection against variants of concern
por: Ma, Qinhai, et al.
Publicado: (2023)

Multiple sclerosis-disease modifying therapies affect humoral and T-cell response to mRNA COVID-19 vaccine
por: Dominelli, Federica, et al.
Publicado: (2022)

The Current Landscape of mRNA Vaccines Against Viruses and Cancer–A Mini Review
por: Ladak, Reese Jalal, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_dlovpel7efcmdgg2c3ttr7buam